Project Grant R21EB040308
Award Date 9/1/26
Completion Date 6/30/28
Dollars Obligated $231K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
- Federal Grant Award Summary Colorado State University received a $413,067 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective September 1, 2025, through August 31, 2027. The project aims to develop an improved class of electrochemical biosensors utilizing engineered binding proteins to simplify electrode fabrication and enhance...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $773,237 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the adoption, effectiveness, and system-level implications of veno-venous extracorporeal membrane oxygenation (ECMO) for treatment of severe acute respiratory failure. The research combines all-payer utilization data and private payer claims data to characterize ECMO adoption across U.S. hospitals, identify...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Colorado, doing business as University of Colorado-Denver, $624,000 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) on April 1, 2026. The recipient is developing a novel topical delivery technology for ex vivo application to donor hearts prior to transplantation. The technology consists of a polymeric sheet containing...
- This $349,999 federal Project Grant award was provided by the National Science Foundation's (NSF) Engineering program (CFDA 47.041) to The Regents of the University of Colorado, doing business as the University of Colorado-Denver. The award aims to develop a new biomaterial platform to investigate how the extracellular matrix influences airway basal stem cell self-renewal and differentiation. This research seeks to create a material that simulates the composition and stiffness of lung tissue,...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Regents of the University of Colorado $190,113 on September 2, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to design synthetic pro-domains for TGF superfamily growth factors that can be activated by external spatiotemporal cues, enabling safer therapeutic deployment of these proteins across wound healing, bone regeneration, and other...
- The National Heart, Lung, and Blood Institute awarded The Washington University $759,584 on September 1, 2026, for research developing high-density diffuse optical tomography (HD-DOT) methods for bedside neuroimaging of brain health in children undergoing extracorporeal membrane oxygenation (ECMO) support. This award is made under the Cardiovascular Diseases Research program (CFDA 93.837). The research aims to advance HD-DOT imaging to evaluate functional connectivity and cerebral oxygenation in...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts $425,971 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 6, 2026, to develop a biomaterials-integrated microphysiological bone marrow chip model. The award funds development of a silicon-based perfusion chip platform that integrates demineralized bone paper and inverted colloidal crystal hydrogel scaffolds to recapitulate the structural and functional interdependence of bone and bone...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $673,345 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct THRIVE, a mechanistic analysis of transfusion and hemolysis-related injury in pediatric extracorporeal membrane oxygenation (ECMO). The award funds analysis of data from the TITRE multicenter trial, which enrolled over 220 children on ECMO and collected time-resolved plasma...
- The National Heart, Lung, and Blood Institute awarded Worcester Polytechnic Institute $532,935 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the endothelial glycocalyx in sepsis-induced coagulopathy. The research targets sepsis-associated coagulopathy, a condition characterized by uncontrolled thrombosis, large vessel occlusion, and stroke that resists traditional anticoagulation therapies. The project will examine how sepsis...